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ABSTRACT
Background: Risk stratification can contribute to
individualised optimal secondary prevention in patients
with cerebrovascular disease.
Objective: To prospectively investigate the prediction of
the Essen Stroke Risk Score (ESRS) and a pathological
Ankle Brachial Index (ABI) in consecutive patients
hospitalised with acute ischaemic stroke or transient
ischaemic attack (TIA) in 85 neurological stroke units
throughout Germany.
Methods: 852 patients were prospectively documented
on standardised case report forms, including assessment
of ESRS and ABI. After 17.5 months, recurrent cerebro-
vascular events, functional outcome or death could be
assessed in 729 patients predominantly via central
telephone interview.
Results: After discharge from the documenting hospital,
recurrent stroke occurred in 41 patients (5.6%) and
recurrent TIA in 15 patients (2.1%). 52 patients (7.1%)
had died, 33 (4.5%) from cardiovascular causes. Patients
with an ESRS >3 (vs ,3) had a significantly higher risk
of recurrent stroke or cardiovascular death (9.7% vs 5.1%;
odds ratio (OR) 2.00, 95% confidence interval (CI) 1.08 to
3.70) and a higher recurrent stroke risk (6.9% vs 3.7%; OR
1.93, 95% CI 0.95 to 3.94). Patients with an ABI (0.9
(vs .0.9) had a significantly higher risk of recurrent
stroke or cardiovascular death (10.4% vs 5.5%; OR 2.00,
95% CI 1.12 to 3.56) and a higher recurrent stroke risk
(6.6% vs 4.6%; OR 1.47, 95% CI 0.76 to 2.83).
Conclusion: Our prospective follow-up study shows a
significantly higher rate of recurrent stroke or cardiovas-
cular death and a clear trend for a higher rate of recurrent
stroke in patients with acute cerebrovascular events
classified as high risk by an ESRS >3 or a pathological
ABI.
Because of the aging population, the incidence of
ischaemic stroke (IS) is increasing in industrialised
countries with a significant burden from an
individual as well as a public health perspective.
1
In contrast with the incidence of first ever stroke,
which is still expected to rise due to an increasing
life expectancy,
2 the rate of recurrent stroke is
more susceptible to medical treatment or preven-
tive measures and therefore could be effectively
reduced.
34 While predictive models have already
proven their usefulness in patients with myocar-
dial infarction and atrial fibrillation, they are still
hardly used in treatment decisions following IS or
transient ischaemic attack (TIA).
Validated scores exist for the prediction of first
stroke,
56as well as for the prediction of recurrent
(cerebro)vascular events.
7–9 Recently, the Essen
Stroke Risk Score (ESRS
10) was derived from the
data subset of 6433 cerebrovascular patients in the
large scale Clopidogrel versus Aspirin in Patients at
Risk of Ischaemic Events (CAPRIE) trial.
11 On a
linear 10 point scale, the ESRS, as presented in
table 1, predicts short term (1 year) risk of
recurrent stroke. The low risk category (score 0–
2) and the higher risk category (score >3) can
easily be distinguished. Because the ESRS has been
developed and validated only in populations from
randomised controlled trials with strict inclusion
and exclusion criteria, we performed a prospective
validation in the Systemic Risk Score Evaluation in
Ischaemic Stroke Patients (SCALA) study on
patients with IS and TIA routinely admitted to
certified German stroke units.
12 At baseline, we
also assessed the ankle brachial index (ABI) which
is an easy to use, inexpensive and reliable tool to
identify patients with high atherosclerotic burden
and thus high cardiovascular risk. Among trained
investigators, test–retest reliability of the ABI is
excellent, and a series of large scale epidemiological
studies have shown a strong correlation between
low ABI scores and (cardiovascular) mortality.
13 14
Current guidelines of the American Heart
Association thus recommend the ABI for screening
of asymptomatic patients to identify and treat an
increased risk of coronary artery disease and
stroke.
15 Similarly, a strong association was demon-
strated between a low ABI and an increased
incidence of ischaemic stroke although sensitivity
was low.
13 16–18 However, only one study so far has
assessed the prognostic value of the ABI in patients
with acute cerebrovascular events.
19 The aims of
the present longitudinal study therefore were to
validate the prediction of the ESRS with the
established cut-off >3 for high risk patients and
to investigate the prediction of a pathological ABI
for future cerebrovascular events and vascular
death in patients after an acute IS or TIA.
METHODS
This prospective observational cohort study
(Systemic Risk Score Evaluation in Ischaemic
Stroke Patients (SCALA)) was conducted in 85
certified German neurological stroke units, each of
which documented 10 consecutive patients with
acute IS or TIA on standardised case report forms,
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results of baseline data collection have been described pre-
viously.
12 In short, the following exclusion criteria were applied:
primary cerebral haemorrhage, intubation and refusal or
inability to provide informed consent. Patients were treated
according to best current knowledge, and management was not
delayed or altered by participation in this study. Patients
provided written informed consent for study participation. The
study was approved by the ethics committee of the University
of Essen and conducted according to the national data
protection legislation. The ESRS is a simple sum score calculated
as follows: 2 points for age .75 years, each 1 point for age
>65–75, arterial hypertension, diabetes mellitus, previous
myocardial infarction, other cardiovascular disease (except
myocardial infarction and atrial fibrillation), peripheral arterial
disease, current or past (,5 years) smoking and previous TIA or
ischaemic stroke in addition to qualifying event. The ABI was
obtained after a 5 min rest in the supine position from systolic
blood pressure readings by Doppler sonography at the ankle
(posterior and anterior tibial artery) and at the brachial artery.
The highest systolic blood pressure in each leg was then divided
by the average systolic pressure in both arms (unless there was a
discrepancy of >10 mm Hg between the two arms).
A central follow-up interview via telephone (n=649) or
written questionnaire (n=80) was performed in 729 partici-
pants after 17.5 (SD 0.88) months. No follow-up was available
for 123 patients (14.4%) either because they did not consent to
follow-up (n=112) or were reportedly alive but could not be
reached (n=11). Follow-up included screening for recurrent
cerebrovascular events and assessment of functional disability
scales (Barthel Index, modified Rankin Scale (mRS)) or cause of
death. In the case of a recurrent cerebrovascular event or death,
confirmation was sought from the family physician, treating
hospital or local death registries. Only events after discharge
from the documenting hospital were considered.
Statistics
Categorical variables are presented as percentages and contin-
uous variables as mean (SD) and/or median (quartiles). The x
2
test and Fisher’s exact test, as appropriate, were used for
comparison of categorical variables. The Wilcoxon rank sum
score was used for comparison of non-normally distributed
variables. If any variable was not available for all patients, only
valid cases were reported. We calculated the time of event free
survival by Kaplan-Meier (KM) estimates. To evaluate the
performance of the ESRS and ABI, we calculated the area under
the curve (AUC) by c statistic and calibration x
2 (survival
modified Hosmer–Lemeshow). An AUC of 0.5 indicates no
discrimination, and an AUC of 1.0 indicates perfect discrimina-
tion. Analyses were done with SAS V.8.2 and SPSS V.14.0.2.
RESULTS
The 85 centres listed in the appendix (available online)
consecutively included 852 patients with a mean age of 67.1
(SD 12.4) years and a diagnosis of IS in 82.9% and TIA in 17.1%.
Most index events (89.7%) had occurred within the past 7 days
prior to study inclusion. Stroke aetiology was classified as large
artery disease in 26.0%, small vessel disease in 27.2%,
cardioembolic in 23.9% and other or undetermined aetiology
in 22.9% of patients. Other baseline characteristics have been
reported previously.
12 Follow-up after 17.5 (SD 0.88) months
was possible in 729 patients (85.6%), 17.4% with TIA and 82.6%
with IS. Compared with patients who were followed-up, those
without follow-up were significantly older (p=0.043), more
often had a pathological ABI (66.7% vs 52.8%; p,0.005) and
had more severe baseline stroke severity on the National
Institutes of Health-Stroke Scale (mean 6.96 vs. 4.96;
Table 1 Baseline characteristics on the Essen Stroke Risk Score
(ESRS) for patients who were and were not followed-up
Risk factor (points allocated)
With follow-up
(n=729)
Without follow-up
(n=123)
Age 65–75 years (%) (1 point) 35.9 33.3
Age .75 years (%) (2 points) 26.0 36.6*
Arterial hypertension (%) (1 point) 70.4 73.8
Diabetes mellitus (%) (1 point) 26.9 22.8
Previous MI (%) (1 point) 17.1 19.7
Other cardiovascular disease (except MI
and atrial fibrillation) (%) (1 point)
36.8 30.1
PAD (%) (1 point) 10.3 10.6
Smoker (%) (1 point) 24.9 23.9
Previous TIA or ischaemic stroke
in addition to qualifying event (%) (1 point)
25.4 30.1
Mean ESRS sum score 2.96 3.06
*Significant at p,0.05.
MI, myocardial infarction; PAD, peripheral arterial disease; TIA, transient ischaemic
attack.
Figure 1 Survival free of recurrent stroke during follow-up in patients
with an Essen Stroke Risk Score (ESRS) ,3 versus those with a score
>3 (n=700).
Figure 2 Survival free of recurrent stroke or cardiovascular death
during follow-up in patients with an Essen Stroke Risk Score (ESRS) ,3
versus those with a score >3 (n=700).
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their overall ESRS sum score (table 1).
A recurrent fatal or non-fatal stroke was reported by or in 41
patients (5.6%) and a recurrent TIA by 15 patients (2.1%).
Confirmation of these events by the family practitioner or
treating hospital was obtained in 37 and 11 patients, respectively.
One event occurred during carotid endarterectomy which,
together with endovascular stenting, was performed in 32
patients. Recurrent stroke or cardiovascular death occurred in 60
patients. Overall, 52 patients (7.1%) died during follow-up (seven
because of the initial stroke, 12 because of a recurrent stroke, five
because of myocardial infarction, nine because of other cardio-
vascular events, 13 because of other causes and six asa result of an
unknown cause). Of 677 surviving patients, 179 (26.4%) had not
regained functional independence (mRS .2), 85 patients (12.6%)
were largely independent (mRS 2), 398 patients (58.8%) reported
no or only minor disability (mRS ,2) and no information on
functional outcome was available in 15 patients (2.2%). Surviving
patients with a recurrent stroke had a significantly worse
functional status on follow-up (median mRS 4) compared with
event free patients (median mRS 1). No antithrombotic medica-
tion at follow-up was reported by 44 patients (6.5%). A total of
287 patients (42.4%) were receiving aspirin, 148 (21.9%)
phenprocoumon or warfarin (seven with additional aspirin), 107
(15.8%) clopidogrel(12withadditionalaspirin), 52(7.7%)aspirin/
dipyridamol, two (0.3%) heparin and eight (1.2%) various study
medications (medication not further specified in 29 patients).
Completeinformationforcalculation oftheESRS wasavailablein
700 patients and for the ABI in 692 patients. Recurrent stroke
occurred in 11 (3.7%) of 296 patients with ESRS ,3 (or 17/5.7%
including TIA) compared with 28 (6.9%) (or 35/8.7% including
TIA) of 404 patients with ESRS >3 (odds ratio (OR) for stroke
1.93, 95% confidence interval (CI) 0.95 to 3.94). The survival
proportion freeof recurrent strokestratified bythe ESRS isshown
in fig 1. The AUC assessed by c statistics was 0.56 (NS). The risk
of the combined vascular endpoint recurrent stroke or cardiovas-
cular death was significantly higher in patients with ESRS >3( 3 9
events/9.7%) compared with patients with ESRS ,3 (15 events/
5.1%; OR 2.00, 95% CI 1.08 to 3.70; p=0.031). Stratified KM
estimates are shown in fig 2. The AUC assessed by c statistics was
0.61 (95% CI 0.54 to 0.69; p=0.006).
Recurrent stroke occurred in 16 (4.6%) of 346 patients with
an ABI .0.9 (or 20/5.8% including TIA) compared with 23
(6.6%) (or 32/9.2% including TIA) of 346 patients with an ABI
(0.9 (OR for stroke 1.47, 95% CI 0.76 to 2.83) which was
mainly due to the high stroke risk of 7.6% in 170 patients with
an ABI ,0.6. The survival proportion free of recurrent stroke
stratified by ABI is shown in fig 3. The AUC assessed by c
statistics was 0.56 (NS). The risk of the combined vascular end
point was significantly higher in patients with ABI (0.9 (36
events/10.4%) compared with patients with ABI .0.9 (19
events/5.5%; OR 2.00, 95% CI 1.12 to 3.56; p=0.024). Stratified
KM estimates are shown in fig 4. The AUC assessed by c
statistics was 0.61 (95% CI 0.53 to 0.69; p=0.006). The
correlation between the ESRS and ABI in patients with follow-
up was low (r=0.166, p,0.001). The combination of a high risk
on both ESRS and ABI did not result in an improved risk
prediction for stroke (6.7% vs 5.2%; OR 1.31, 95% CI 0.67 to
2.54; p=0.482) or for the combined vascular end point (10.8%
vs 6.3%; OR 1.79, 95% CI 1.02 to 3.15; p=0.048).
No significant differences or relevant trends in the risk of
recurrent stroke were found for different stroke aetiologies
according to the TOAST classification (fig 5).
Figure 3 Survival free of recurrent stroke during follow-up in patients
with an Ankle Brachial Index (ABI) .0.9 versus those with an index of
0.6–0.9 and ,0.6 (n=692).
Figure 4 Survival free of recurrent stroke or cardiovascular death
during follow-up in patients with an Ankle Brachial Index (ABI) .0.9
versus those with an index of 0.6–0.9 and ,0.6 (n=692).
Figure 5 Survival free of recurrent stroke during follow-up stratified by
aetiology (large artery atherosclerosis (laa, n=178), cardiac embolism
(ce, n=163), small vessel disease (svd, n=209) and other/
undetermined (o/u, n=160).
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In this study, we evaluated the ESRS and ABI for identification
of patients at high risk of stroke or cardiovascular death after a
preceding cerebrovascular ischaemic event. Only a few prog-
nostic instruments for identification of cerebrovascular patients
at high risk have been prospectively validated to date and are
rarely used in clinical routine. We prospectively assessed the
ESRS and ABI in consecutive patients with acute TIA or IS
admitted to a large number of acute stroke units covering all
geographic areas in Germany. Patients were included consecu-
tively provided they could give informed consent, representing
approximately 80–90% of unselected patients admitted to
German stroke units. Thus with the exception of severely
aphasic and severely ill patients, the population in our study can
be regarded as representative of acute stroke units. While both
scoring instruments (ABI and ESRS) are simple to apply, their
combination did not improve overall prediction, which may be
due to their low correlation (Pearson correlation coefficient
0.21)
12 or the low event rates during follow-up, resulting in a
wide CI. Similarly, stratification by type of stroke according to
the TOAST criteria in our study did not show any clear trend in
risk of recurrent stroke and therefore would not add any
predictive accuracy.
Our study on ESRS and ABI in cerebrovascular patients has
three major limitations: we did not assess and therefore were
unable to consider recurrent cerebrovascular events or cardio-
vascular death during the acute hospital stay, resulting in lower
event rates than expected from other hospital based studies.
Because of the low number of stroke events during follow-up,
we failed to demonstrate statistically significant differences
between high risk and low risk patients for the end point of
recurrent stroke, although clear trends for higher stroke
recurrence were seen in patients with ESRS >3 or ABI ,0.6.
Statistically significant differences were found for the combined
vascular end point with higher event rates in patients with
ESRS >3 or ABI (0.9. Unfortunately, the number of end point
events was insufficient to provide meaningful risk stratifications
of smaller ESRS or ABI categories and confidence intervals
remain wide for the KM estimates which can explain the
delayed segregation of the KM curves. A higher follow-up
percentage than 85.6% would have been unlikely to change our
results because most patients without follow-up simply did not
provide informed consent for follow-up and citizen registries
were consulted before any patients was considered lost.
Furthermore, the rates of recurrent stroke in the high and low
risk strata of the ESRS were very similar to the CAPRIE data set
initially used for model development
10 and the ESPS-2 data used
for its retrospective validation
20 and therefore confirm its
predictive value in consecutive patients treated with modern
prevention strategies in acute stroke units. Both retrospective
analyses of CAPRIE and ESPS2 could also show a steady
increase in the risk of stroke with increasing ESRS sum score
and an amplified (although non-significant) benefit of clopido-
grel or aspirin plus dipyridamole over aspirin in patients with
ESRS >3. Secondly, atrial fibrillation was not investigated as an
independent predictor or included on development of the ESRS.
However, atrial fibrillation has not been identified as an
independent risk factor in other follow-up studies either,
78
and the risk of stroke recurrence in patients with a cardioem-
bolic stroke aetiology (most of whom had atrial fibrillation) was
not significantly different from other aetiologies. On the other
hand, we did not exclude patients with cardioembolic stroke
aetiology. Although exclusion of patients with non-athero-
thrombotic stroke might result in a better prediction of the
ESRS and ABI, we aimed to demonstrate the general applic-
ability of the two instruments without additional diagnostic
work-up to exclude cardioembolic aetiologies.
Finally, the prediction of the ESRS was based solely on clinical
variables, while the ABI assesses generalised atherosclerosis only,
which is responsiblefor lessthanhalf of allstrokes. In comparison,
another clinical scoring system, developed by Hankey et al
predicting various vascular events (stroke, coronary events,
vascular death) at 1 and 5 years later found an AUC value of
0.65 on external validation in the UK–TIA cohort.
21 Likewise, the
SPI-II found an AUC of 0.63 for prediction of stroke or death
within 2 years in independent research populations.
7 Both scores
therefore have comparable predictive accuracy compared with our
scores for the combined endpoint recurrent stroke/cardiovascular
death. Neither one of these scales however has been prospectively
validated for prediction of stroke in a non-research population. We
could not compare the predictive accuracy between these scales
and the ESRS in our study population because not all variables
from the other scales had been prospectively documented and the
number of outcome events would have been too small to detect
any statistically significant differences. As previously reported, an
important finding in our study was the high prevalence of
pathologicalABIvaluesinmorethanhalfofallpatients,whichcan
be attributed to the inclusion of consecutive patients with acute
ischaemic events as well as to a more comprehensive definition of
pathological ABI values ((0.9 vs .0.9) in our trial.
12 Although
prediction of stroke could be improved by dichotomising the ABI
at 0.6, allpatients with a low ABIshould be considered at high risk
for any cardiovascular event, including death.
19
In conclusion, the ESRS is convenient to use, targets a
distinctly important clinical outcome and is reasonably accurate
for clinical stratification of high risk patients. Both the ESRS
and ABI seem suitable for routine application to increase
awareness of recurrent stroke risk in cerebrovascular patients.
Whether patients at high risk according to the ABI or ESRS
benefit from intensified medical prevention strategies is difficult
to assess because of the high number of end points needed.
Because of its potential for optimising secondary prevention
strategies, this question is of major relevance to public health
decisions and should be assessed in future secondary prevention
trials. In addition, high risk patients may constitute the ideal
target population for clinical trials of more aggressive medical
prevention strategies which may also imply a higher associated
risk. Moreover, by including only patients at higher risk of
recurrent stroke, future trials could achieve the necessary
number of endpoint events with fewer patients or within
shorter follow-up periods.
Acknowledgements: We would like to thank the participating physicians for their
contributions (see appendix online). Central follow-up was performed by the
Department of Neurology, University of Duisburg-Essen, with support for statistical
analysis by Winicker Norimed, Nu ¨rnberg.
Funding: This study was funded by Sanofi-Aventis, Berlin, Germany. The company
was involved in the original concept, design, choice of investigators, control of
allocation schedule, conduct of the trial, collection and monitoring of baseline data
under close supervision by the members of the steering committee (all of whom are
listed as authors on this paper).
Competing interests: None.
Ethics approval: The study was approved by the ethics committee of the University
of Essen and conducted according to national data protection legislation.
REFERENCES
1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause
1990–2020: Global Burden of Disease Study. Lancet 1997;349:1498–504.
2. Wolfe CD. The impact of stroke. Br Med Bull 2000;56:275–86.
Research paper
1342 J Neurol Neurosurg Psychiatry 2008;79:1339–1343. doi:10.1136/jnnp.2008.1460923. Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients
with ischemic stroke or transient ischemic attack: a statement for healthcare
professionals from the American Heart Association/American Stroke Association
Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and
Intervention: the American Academy of Neurology affirms the value of this guideline.
Stroke 2006;37:577–617.
4. The European Stroke Organization (ESO) Executive Committee and the ESO
Writing Committee. Guidelines for managemant of ischaemic stroke and transient
ischemic attack 2008. Cerebrovasc Dis 2008;25:457–507.
5. D’Agostino RB, Wolf PA, Belanger AJ, et al. Stroke risk profile:
adjustment for antihypertensive medication. The Framingham Study. Stroke
1994;25:40–3.
6. Moons KG, Bots ML, Salonen JT, et al. Prediction of stroke in the general population
in Europe (EUROSTROKE): Is there a role for fibrinogen and electrocardiography?
J Epidemiol Community Health 2002;56(Suppl 1):i30–6.
7. Kernan WN, Viscoli CM, Brass LM, et al. The stroke prognosis instrument II (SPI-II) :
A clinical prediction instrument for patients with transient ischemia and nondisabling
ischemic stroke. Stroke 2000;31:456–62.
8. Hankey GJ, Slattery JM, Warlow CP. Transient ischaemic attacks: which patients
are at high (and low) risk of serious vascular events? J Neurol Neurosurg Psychiatry
1992;55:640–52.
9. Johnston SC, Rothwell PM, Nguyen-Huynh MN, et al. Validation and refinement of
scores to predict very early stroke risk after transient ischaemic attack. Lancet
2007;369:283–92.
10. Diener HC, Ringleb PA, Savi P. Clopidogrel for the secondary prevention of stroke.
Expert Opin Pharmacother 2005;6:755–64.
11. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus
aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329–39.
12. Weimar C, Goertler M, Ro ¨ther J, et al. Systemic risk score evaluation in ischemic
stroke patients (SCALA): A prospective cross sectional study in 85 German stroke
units. J Neurol 2007;254:1562–8.
13. Doobay AV, Anand SS. Sensitivity and specificity of the ankle-brachial index to
predict future cardiovascular outcomes: a systematic review. Arterioscler Thromb
Vasc Biol 2005;25:1463–9.
14. Diehm C, Lange S, Darius H, et al. Association of low ankle brachial index with high
mortality in primary care. Eur Heart J 2006;27:1743–9.
15. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice guidelines for the
management of patients with peripheral arterial disease (lower extremity, renal,
mesenteric, and abdominal aortic): a collaborative report from the American
Association for Vascular Surgery/Society for Vascular Surgery, Society for
Cardiovascular Angiography and Interventions, Society for Vascular Medicine and
Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice
Guidelines (Writing Committee to Develop Guidelines for the Management of Patients
With Peripheral Arterial Disease): endorsed by the American Association of
Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood
Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and
Vascular Disease Foundation. Circulation 2006;113:e463–654.
16. Abbott RD, Rodriguez BL, Petrovitch H, et al. Ankle-brachial blood pressure in elderly
men and the risk of stroke: the Honolulu Heart Program. J Clin Epidemiol
2001;54:973–8.
17. Tsai AW, Folsom AR, Rosamond WD, et al. Ankle-brachial index and 7-year ischemic
stroke incidence: the ARIC study. Stroke 2001;32:1721–4.
18. Murabito JM, Evans JC, Nieto K, et al. Prevalence and clinical correlates of
peripheral arterial disease in the Framingham Offspring Study. Am Heart J
2002;143:961–5.
19. Agnelli G, Cimminiello C, Meneghetti G, et al. Low ankle-brachial index predicts an
adverse 1-year outcome after acute coronary and cerebrovascular events. J Thromb
Haemost 2006;4:2599–606.
20. Diener HC. Modified-release dipyridamole combined with aspirin for secondary
stroke prevention. Aging Health 2005;1:19–26.
21. Hankey GJ, Slattery JM, Warlow CP. Can the long term outcome of individual
patients with transient ischaemic attacks be predicted accurately? J Neurol
Neurosurg Psychiatry 1993;56:752–9.
BMJ Masterclasses
BMJ Masterclasses are educational meetings designed specifically to meet the learning needs of
doctors. They help doctors keep up to date with the latest evidence and recent guidelines in major
clinical areas, enabling them to use the latest evidence to make better decisions. The latest evidence,
recent guidelines and best practice are delivered in an interactive and informative manner by leading
experts. The speakers are specifically chosen as highly-skilled communicators who can authoritatively
enthuse the audience and interpret the latest research and guidelines into practical tips for busy
doctors. BMJ Masterclasses have proved a huge hit with clinicians, with many saying they have
influenced their clinical practice.
http://masterclasses.bmj.com/
Research paper
J Neurol Neurosurg Psychiatry 2008;79:1339–1343. doi:10.1136/jnnp.2008.146092 1343